Taiwan's ScinoPharm is to make an investment in the US firm Tanvex Biologics, with the intention of building up joint capacity for the manufacture of biosimilars in the US market.
The investment will take the form of assets, intellectual property and cash, and includes an equity stake in Tanvex. The...


![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)




